A Functional Variant in the MTOR Promoter Modulates Its Expression and Is Associated with Renal Cell Cancer Risk

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Cao, Qiang ^a   Ju, Xiaobing ^a   Li, Pu ^a   Meng, Xiaoxin ^a   Shao, Pengfei ^a   Cai, Hongzhou ^a   Wang, Meilin ^b   Zhang, Zhengdong ^b   Qin, Chao ^a   Yin, Changjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; LUCIFERASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

3' UNTRANSLATED REGION; ADULT; AKT1 GENE; AKT2 GENE; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MTOR GENE; PI3KCA GENE; PROMOTER REGION; PTEN GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC VARIATION; GENOTYPE; HEK293 CELLS; HELA CELLS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REGRESSION ANALYSIS; RISK; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84870386863     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050302     Document Type: Article

References (29)

1. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, et al. (2011) The Epidemiology of Renal Cell Carcinoma. Eur Urol.
2. Cohen HT, McGovern FJ, (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-2490.
3. Chow WH, Dong LM, Devesa SS, (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7: 245-257.
4. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, et al. (2010) VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221: 125-138.
5. Ollerenshaw M, Page T, Hammonds J, Demaine A, (2004) Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet 153: 122-126.
6. Bruyere F, Hovens CM, Marson MN, d'Arcier BF, Costello AJ, et al. (2010) VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol 184: 1273-1278.
7. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, et al. (2011) Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43: 60-65.
8. Qin C, Cao Q, Ju X, Wang M, Meng X, et al. (2012) The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol 23: 981-989.
9. Cao Q, Qin C, Ju X, Meng X, Wang M, et al. (2011) Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population. Mutagenesis.
10. Jiang BH, Liu LZ, (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102: 19-65.
11. Schlessinger J, (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
12. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
13. Altomare DA, Testa JR, (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464.
14. Arcaro A, Guerreiro AS, (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8: 271-306.
15. Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, et al. (2002) Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22: 3842-3851.
16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
17. Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, et al. (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28: 2131-2136.
18. Wang W, Pan X, Huo X, Yan F, Wang M, et al. (2012) A functional polymorphism C-1310G in the promoter region of Ku70/XRCC6 is associated with risk of renal cell carcinoma. Mol Carcinog.
19. Wang M, Zhang Z, Zhu H, Fu G, Wang S, et al. (2008) A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res 14: 3633-3640.
20. Kruck S, Bedke J, Hennenlotter J, Ohneseit PA, Kuehs U, et al. (2010) Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol Rep 23: 159-163.
21. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, et al. (2006) The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66: 5130-5142.
22. Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, et al. (2011) Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 9: 133.
23. Gately K, Al-Alao B, Dhillon T, Mauri F, Cuffe S, et al. (2012) Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer 75: 217-222.
24. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, et al. (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788.
25. Marioni G, Staffieri A, Giacomelli L, Lionello M, Guzzardo V, et al. (2011) Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence. Histopathology 58: 1148-1156.
26. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, et al. (2007) Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13: 4795-4799.
27. Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, et al. (2011) Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 29: 2557-2564.
28. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, et al. (2011) Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17: 620-629.
29. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.